Update On Hcm: Does Mavacamten Challenge Septal Reduction Therapy

Update on HCM: Does Mavacamten Challenge Septal Reduction Therapy?

New Treatment Option for Hypertrophic Cardiomyopathy | Mavacamten

Drug Reduces the Need for Surgery in Nearly 90% of Patients with HCM, Cleveland Clinic Study Shows

Cleveland Clinic

Early septal reduction therapy for patients with obstructive hypertrophic cardiomyopathy

Septal Myectomy and Residual Leaflet Excision for Hypertrophic Cardiomyopathy

NYU Langone Health

Does Mavacamten mean more surgeries?

Cardiomyopathy UK

Mavacamten for HCM

HCM Update

Mavacamten for HCM

Cardiomyopathy UK

Health check: 'Promising results' for heart drug

WFAA

Mavacamten for HoCM

Cardiomyopathy UK

2024 Guideline for the Management of Hypertrophic Cardiomyopathy

VALOR-HCM: Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Mavacamten a Novel DiseaseSpecific Treatment for Hypertrophic Obstructive Cardiomyopathy

BP International

The EXPLORER-HCM study: mavacamten for obstructive HCM

Video Journal of Biomedicine

Could Mavacamten be Used as a Prophylactic?

Cardiomyopathy UK

Septal Reduction Therapies for HCM in Era of Novel Pharmacotherapeutics (Srihari Naidu, MD) 09/23/21

Houston Methodist DeBakey CV Education

ESC TV at #ACC22 - Expert Insights on VALOR-HCM and MAVA-LTE Study

European Society of Cardiology

#CardioGuy #Mavacamten #cardio #cardiology #cardiomyopathy #medicine #study #randomized #trail #usa

New Drug Therapies – Professor Perry Elliott, Hosted by Libby Jarman

Cardiomyopathy UK